Analysis: What’s Next for China’s Generic Drug Industry?

(Blue View) — Chinese drugmaker Jiangsu Hengrui Pharmaceuticals Co. Ltd. won U.S. regulatory approval in May to market its iodixanol injection for cancer, bringing a long-overdue buzz to China’s silent generic drug industry.

Over the past few years, innovative drug development has been vigorously promoted with capital and policies in China. Meanwhile, the generic drug industry has been shrinking due to strict price controls under China’s national drug procurement system. In 2019, Hengrui announced plans to stop all generic drug projects and shift to innovation.